文献速递神经肌肉病

免疫抑制治疗对眼肌型重症肌无力泛化风险的影响:一项回顾性队列研究

Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
PubMed 文献 · Neurology · 2024-07-30

这项回顾性队列研究纳入154例纯眼肌型重症肌无力成人患者,平均随访87.4±73个月,43例(28%)出现泛化。倾向评分匹配、IPTW及时变暴露模型显示,泼尼松和任何免疫抑制剂均与泛化风险降低相关,支持早期使用免疫抑制。

要点

  • 泼尼松与泛化风险降低相关,匹配模型HR 0.43(95%CI 0.19-1.06),IPTW模型HR 0.46(95%CI 0.21-0.89)。
  • 任何免疫抑制剂与泛化风险降低相关,匹配模型HR 0.30(95%CI 0.11-0.77),IPTW模型HR 0.32(95%CI 0.14-0.70)。
  • 本研究提供III级证据表明皮质类固醇或非甾体免疫抑制剂可降低眼肌型重症肌无力泛化风险。

核心结论

  • 眼肌型重症肌无力患者接受类固醇或非类固醇免疫抑制治疗与随时间推移发生泛化症状的风险降低相关,支持在该人群中早期使用免疫抑制。

研究设计与样本

  • 回顾性研究纳入连续成人纯眼肌型重症肌无力患者,随访至少6个月,共154例,平均随访87.4±73个月。
  • 采用倾向评分匹配泼尼松或任何免疫抑制剂治疗组与对照组,并使用IPTW非匹配模型及时变暴露模型,Cox比例风险模型估计泛化HR。

主要发现

  • 43例(28%)出现泛化,从诊断到泛化的平均时间为24.2±24.1个月。
  • 泼尼松组较对照组泛化风险降低:匹配模型HR 0.43(95%CI 0.19-1.06),IPTW模型HR 0.46(95%CI 0.21-0.89),时变暴露模型HR 0.44(95%CI 0.23-0.81)。
  • 任何免疫抑制剂组较对照组泛化风险降低:匹配模型HR 0.30(95%CI 0.11-0.77),IPTW模型HR 0.32(95%CI 0.14-0.70),IPTW时变暴露模型HR 0.35(95%CI 0.15-0.80)。

关键数值与推荐

  • 本研究提供III级证据表明眼肌型重症肌无力使用皮质类固醇或非甾体免疫抑制剂可降低泛化风险。

临床怎么用

  • 作者认为,眼肌型重症肌无力患者接受类固醇和非类固醇免疫抑制治疗与泛化症状风险降低相关,支持早期使用免疫抑制。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDS AND OBJECTIVES: Early use of immunosuppression has been suggested to prevent generalization of ocular myasthenia gravis (OMG), but high-quality evidence is limited in this regard. We examined whether treatment with prednisone and other immunosuppressants reduce the risk of generalization in OMG. METHODS: This is a retrospective study of consecutive adults with pure OMG who had a minimum 6 months of follow-up. The main outcome was the time to developing generalized symptoms. We used propensity scores to create matched data sets of patients treated with prednisone or any immunosuppressant vs controls. We also used unmatched models with inverse probability of treatment weights (IPTW) and variable exposure times. We used Cox proportional hazards model to estimate hazard ratio (HR) for generalization, comparing treated patients vs controls. RESULTS: A total of 154 patients were included, with a mean follow-up of 87.4 ± 73 months since onset. Forty-three (28%) were generalized, and mean time to generalization from diagnosis was 24.2 ± 24.1 months. Patients who received prednisone had lower risk of generalization than controls, with pooled HR 0.43 (95% CI 0.19-1.06) for the matched model, HR 0.46 (95% CI 0.21-0.89) for the IPTW model, and for HR 0.44 (95% CI 0.23-0.81) for the time-dependent exposure model. Patients who received any immunosuppressant had lower risk of generalization, with HR 0.30 (95% CI 0.11-0.77), 0.32 (95% CI 0.14-0.70), and 0.35 (95% CI 0.15-0.80) for the matched, IPTW, and IPTW-varying exposure models, respectively. DISCUSSION: Our study provides evidence that steroidal and nonsteroidal immunosuppression in patients with OMG is associated with a reduced risk of developing generalized symptoms over time. This supports the early use of immunosuppression in this population. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that treatment of OMG with corticosteroids or nonsteroidal immunosuppressants reduces the risk of generalization.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Menon D, Alharbi M, Katzberg HD, et al. Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study. Neurology. 2024. PMID: 39079067. doi:10.1212/WNL.0000000000209722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。